Celldex Therapeutics, Inc. (NASDAQ: CLDX) reiterated to Outperform with price target $42 by Oppenheimer
Oppenheimer reiterated Celldex Therapeutics, Inc. (NASDAQ: CLDX) to Outperform with price
target $42. Previously Oppenheimer rated Outperform with price target $36 Celldex Therapeutics, Inc. (NASDAQ: CLDX) on 03/04/2014, when the stock price was $27.69.
Celldex Therapeutics, Inc.
(Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.
Funds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies.
Funds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority.
Funds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.